NASDAQ
No price data available for this timeframe.
Stoke Therapeutics, Inc. (STOK) has a price/fcf ratio of 41.85x as of Monday, May 25, 2026. This represents a 613.42% increase compared to its 12-month average of -8.15x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.